Clinical Trial Update: Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) [NA]

View source ↗

Summary

Clinical trial update for Optune (NOVOTTF-100A) + Bevacizumab + Hypofractionated Stereotactic Irradiation in bevacizumab-naive recurrent glioblastoma; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Hypofractionated Stereotactic Irradiation
• OPTUNE

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: RECURRENT GLIOBLASTOMA, Brain Tumor | NA | Status: TERMINATED | Results posted: 2022-02-03